Dr Reddys Laboratories (RDY) EBITDA Margin (2012 - 2026)
Dr Reddys Laboratories (RDY) recorded quarterly EBITDA Margin of 1.5% in Q1 2026, down 90.78% quarter-over-quarter from 16.32% in Q4 2025, and down 1924.0% on a YoY basis from 0.08% in Q1 2025.
Dr Reddys Laboratories (RDY) EBITDA Margin (2012 - 2026) Analysis & Trends
Dr Reddys Laboratories' EBITDA Margin history runs 15 years deep, the most recent figure standing at 1.5% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 1924.0% year-over-year to 1.5%; the TTM figure through Mar 2026 stood at 14.84% (up 367.0% YoY), while the FY2026 annual figure was 15.06%, down 704.0% from the prior year.
- EBITDA Margin was 1.5% for Q1 2026 at Dr Reddys Laboratories, down from 16.32% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 26.14% in Q1 2023 to a low of 2.42% in Q4 2024.
- Historically, EBITDA Margin has averaged 16.03% across 5 years, with a median of 20.6% in 2025.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin plunged 2693 bps in 2024, then soared 2153 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 19.66% in 2022, then plunged by 93 bps to 1.37% in 2023, then slumped by 276 bps to 2.42% in 2024, then surged by 774 bps to 16.32% in 2025, then plunged by 91 bps to 1.5% in 2026.
- The last three EBITDA Margin figures came in at 1.5% (Q1 2026), 16.32% (Q4 2025), and 20.45% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -1.01% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 22.74% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -170.35% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 21.55% |
| 10 | Dr Reddys Laboratories | 122.03 Mn | -51.98 Mn | 368.55 Mn | 1.50% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.50% |
| Dec 31, 2025 | 16.32% |
| Jun 30, 2025 | 20.45% |
| Mar 31, 2025 | 20.75% |
| Dec 31, 2024 | -2.42% |
| Sep 30, 2024 | 3.69% |
| Jun 30, 2024 | 23.36% |
| Mar 31, 2024 | -0.79% |
| Dec 31, 2023 | 1.37% |
| Sep 30, 2023 | 25.97% |
| Jun 30, 2023 | 25.97% |
| Mar 31, 2023 | 26.14% |
| Dec 31, 2022 | 19.66% |
| Sep 30, 2022 | 25.58% |
| Jun 30, 2022 | 25.59% |
| Mar 31, 2022 | 23.40% |
| Dec 31, 2021 | 2.76% |
| Sep 30, 2021 | 17.40% |
| Jun 30, 2021 | 20.98% |
| Mar 31, 2021 | 13.42% |